Posted by Michael Wonder on 28 Mar 2024
Akebia receives FDA approval of Vafseo (vadadustat) tablets for the treatment of anaemia due to chronic kidney disease in adult patients on dialysis
27 March 2024 - Once daily oral HIF-PH inhibitor activates physiologic response to manage anaemia.
Akebia Therapeutics today announced that the US FDA has approved Vafseo (vadadustat) tablets for the treatment of anaemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months.
